Hepatitis C Virus and the Host: A Mutual Endurance Leaving Indelible Scars in Host’s Immunity
Preprint
- 30 November 2023
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Hepatitis C virus (HCV) is diffused worldwide, and it is responsible for potentially severe chronic liver disease and primary liver cancer. Chronic infection remains for life if not spontaneously eliminated and viral persistence profoundly impairs the efficiency of host’s immunity. Attempts have been made to develop an effective vaccine, but efficacy trials have met with failure. The availability of highly efficacious direct acting antivirals (DAA) has shed hopes for progressive elimination of chronic HCV infection; however, this approach requires a global monumental effort. Moreover, DAA treatment does not completely restore the normal immunologic homeostasis. Here we discuss the main immunological features of immune responses to HCV and the epigenetic scars that chronic viral persistence leaves behind.Keywords
All Related Versions
This publication has 102 references indexed in Scilit:
- A prospective study of direct‐acting antiviral effectiveness and relapse risk in HCV cryoglobulinemic vasculitis by the Italian PITER cohortHepatology, 2022
- Adaptive Natural Killer Cell Functional Recovery in Hepatitis C Virus Cured PatientsHepatology, 2020
- Characterizing Hepatitis C Virus–Specific CD4+ T Cells Following Viral‐Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral CureHepatology, 2020
- Negative Regulation of Mitochondrial Antiviral Signaling Protein–Mediated Antiviral Signaling by the Mitochondrial Protein LRPPRC During Hepatitis C Virus InfectionHepatology, 2018
- Persisting risk of hepatocellular carcinoma after hepatitis C virus cure monitored by a liver transcriptome signatureHepatology, 2017
- T-cell immunity and hepatitis C virus reinfection after cure of chronic hepatitis C with an interferon-free antiviral regimen in a chimpanzeeHepatology, 2014
- Hepatitis C virus NS4B protein targets STING and abrogates RIG-I–mediated type I interferon-dependent innate immunityHepatology, 2012
- Activating NK cell receptor expression/function (NKp30, NKp46, DNAM‐1) during chronic viraemic HCV infection is associated with the outcome of combined treatmentEuropean Journal of Immunology, 2011
- Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infectionHepatology, 2007
- Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses†Hepatology, 2005